Trial · NCT00733902

Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	174
Overall Study	STARTED	Tanezumab 2.5 mg	174
Overall Study	STARTED	Tanezumab 5 mg	174
Overall Study	STARTED	Tanezumab 10 mg	175
Overall Study	Treated	Placebo	172
Overall Study	Treated	Tanezumab 2.5 mg	172
Overall Study	Treated	Tanezumab 5 mg	172
Overall Study	Treated	Tanezumab 10 mg	174
Overall Study	COMPLETED	Placebo	10
Overall Study	COMPLETED	Tanezumab 2.5 mg	12
Overall Study	COMPLETED	Tanezumab 5 mg	13
Overall Study	COMPLETED	Tanezumab 10 mg	11
Overall Study	NOT COMPLETED	Placebo	164
Overall Study	NOT COMPLETED	Tanezumab 2.5 mg	162
Overall Study	NOT COMPLETED	Tanezumab 5 mg	161
Overall Study	NOT COMPLETED	Tanezumab 10 mg	164

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00733902/flow